Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration

Journal of Neural Transmission

Volumn 118, Issue 2, 2011, Pages 223-231

  Dexter, David T ^a   Statton, Sarah A ^a   Whitmore, Charlotte ^a   Freinbichler, Wolfhardt ^c   Weinberger, Peter ^c   Tipton, Keith F ^d   Della Corte, Laura ^e   Ward, Roberta J ^a,b,e   Crichton, Robert R ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Brain iron; Deferasirox; Deferiprone; Desferrioxamine; Iron chelators; Parkinson's disease

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; MALE; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; BENZOIC ACIDS; BRAIN; DEFEROXAMINE; FREE RADICALS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; IRON CHELATING AGENTS; MALE; MICRODIALYSIS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; SORBIC ACID; TRIAZOLES;

EID: 79955852987     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0531-3     Document Type: Article

References (37)

1. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB (2007) Therapeutic targets and potential of the novel brain - permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30 for the treatment of Alzheimer's disease. J Neurochem 100:490-502 (Pubitemid 46016026)
2. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator deferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441-1444 (Pubitemid 21902069)
3. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:401-408 (Pubitemid 47026862)
4. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF (2007) Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 29:909-917 (Pubitemid 47241173)
5. Carman LS, Gage FH, Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behaviour. Brain Res 553:275-283
6. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD (2005) 6-Hydroxydopamine-induced alterations in blood-brain permeability. Eur J Neurosci 22:1158-1168
7. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular deferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-1308
8. Crichton RR, Ward RJ (2006) Metal-based neurodegeneration: from molecular mechanisms to therapeutic perspectives. Wiley, Chichester, pp 21-52
9. Datla KP, Bennett RD, Zbarsky V, Ke B, Liang Y, Bahorun HT, Aruoma OI, Dexter DT (2004) The antioxidant drink "effective microorganism-x (EM-X)" pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in a 6-hydroxydopamine lesion model of Parkinson's disease. J Pharma Pharmacol 56:649-654 (Pubitemid 38607657)
10. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 2:1219-1220 (Pubitemid 17156630)
11. Duce JA, Bush AI (2010) Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol 92:1-18
12. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. doi:101186/1750-1326-4-47
13. Freinbichler W, Colivicchi MA, Fattori M, Ballini C, Tipton KF, Linert W, Della Corte L (2008) Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis. J Neurochem 105:738-749 (Pubitemid 351562717)
14. Gerlach M, Double KL, Youdim MB, Riederer P (2006) Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 70:133-42 (Pubitemid 44622190)
15. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716
16. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG et al (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Therapeut 330:679-686
17. Hua Y, Keep RF, Hoff JT, Xi G (2008) Deferoxamine therapy for intracerebral hemorrhage. Acta Neurochir Suppl 105:3-6
18. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI (2008) Cell function impaired by frataxin deficviency are restored by drug-mediated iron relocation. Blood 112:5219-5227
19. Liu G, Men P, Perry G, Smith MA (2009) Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol 610:123-144
20. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9:133-146 (Pubitemid 29056524)
21. McLachlan DR, Smith WL, Kruck TP (1993) Deferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminium. Ther Drug Monit 15:602-607 (Pubitemid 23347259)
22. Mills E, Dong A, Wang F, Xu H (2010) Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem 2(51):1-19
23. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, Australia
24. Perez CA, Tong Y, Guo M (2008) Iron chelators as potential therapeutic agents for Parkinson's disease. Curr Bioact Compd 4:150-158
25. Polsen RJ, Jawed A, Bomford A, Berry H, Williams R (1985) Treatment of rheumatoid arthritis with deferrioxamine: relation between stores of iron before treatment and side effects. B Med J 291:448 (Pubitemid 15012891)
26. Praticò D (2008) Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29:609-615
27. Selim M (2008) Deferoxamine mesylate A new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke 40:S90-S91
28. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254-263 (Pubitemid 37532833)
29. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866-9868 (Pubitemid 27408156)
30. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199-205
31. Stankiewicz JM, Brass SD (2009) Role of iron in neurotoxicity: a cause for concern in the elderly? Curr Opin Clin Nutr Metab Care 12:22-29
32. Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT (2007) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 103(3):1075-1091 (Pubitemid 47568746)
33. Wang, J, Jiang, H, Xie, JX (2007) Ferroportin 1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 25:2766-2772 (Pubitemid 46888831)
34. Ward RJ, Dexter DT, Florence A, Aouad F, Hider R, Jenner P, Crichton RR (1995) Brain iron content of the ferrocene-loaded rat. Biochem Pharmacol 49:1821-1826
35. Ward RJ, Colivicchi MA, Allen R, Schol F, Lallemand F, de Witte P, Ballini C, Della Corte L, Dexter D (2009) Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content. J Neurochem 111:1119-1128
36. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB (2010) Neuroprotective multifunctional iron chelators: from redoxsensitive process to novel therapeutic opportunities. Antioxid Redox Signal 13:919-949
37. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative disease with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325 (Pubitemid 38453534)